Virtu Financial LLC Sesen Bio, Inc. Transaction History

Virtu Financial LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$0.0 - $0.93 $0 - $67,711	72,808 New	72,808 $31,000
Q1 2022 May 17, 2022	SELL	$0.58 - $0.86 $110,891 - $164,425	-191,192 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$0.73 - $1.28 $139,570 - $244,725	191,192 New	191,192 $156,000
Q3 2021 Nov 12, 2021	SELL	$0.77 - $4.91 $56,661 - $361,307	-73,586 Closed	0 $0
Q2 2021 Sep 17, 2021	SELL	$2.18 - $4.66 $508,958 - $1.09 Million	-233,467 Reduced 76.03%	73,586 $340,000
Q1 2021 May 19, 2021	BUY	$1.3 - $3.24 $48,163 - $120,038	37,049 Added 13.72%	307,053 $798,000
Q4 2020 Feb 24, 2021	BUY	$1.01 - $1.77 $161,917 - $283,755	160,314 Added 146.15%	270,004 $365,000
Q3 2020 Dec 11, 2020	BUY	$0.67 - $1.4 $31,243 - $65,284	46,632 Added 73.95%	109,690 $154,000
Q2 2020 Aug 07, 2020	SELL	$0.52 - $0.87 $69,117 - $115,638	-132,918 Reduced 67.82%	63,058 $45,000
Q4 2019 Feb 04, 2020	BUY	$0.89 - $1.5 $72,626 - $122,404	81,603 Added 71.35%	195,976 $204,000
Q3 2019 Nov 20, 2019	SELL	$1.04 - $1.51 $172,551 - $250,531	-165,915 Reduced 59.19%	114,373 $134,000
Q2 2019 Aug 13, 2019	BUY	$0.95 - $2.46 $185,070 - $479,235	194,811 Added 227.91%	280,288 $420,000
Q1 2019 Apr 12, 2019	BUY	$0.69 - $1.47 $58,979 - $125,651	85,477 New	85,477 $88,000
Q4 2018 Jan 16, 2019	SELL	$0.96 - $2.04 $17,248 - $36,652	-17,967 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$1.54 - $2.38 $27,669 - $42,761	17,967 New	17,967 $39,000
Q2 2018 Jul 30, 2018	SELL	$1.04 - $3.29 $39,881 - $126,164	-38,348 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$1.04 - $3.29 $39,881 - $126,164	38,348 New	38,348 $75,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.